Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Exploring Spatial-Temporal Changes in
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02384382 (A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 2, open-label, single-arm study of 18f-sodium fluoride pet/ct bone imaging in enzalutamide-treated chemotherapy-naïve patients with bone-metastatic castration-resistant prostate cancer
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.European urology oncology · 2024Trial
- Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.Journal for immunotherapy of cancer · 2023Trial
- Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.Investigational new drugs · 2026Article
- Liquid Biopsies and Molecular Imaging for Precise Cancer Management.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response.Advances in radiation oncology · 2025Article
- Synergizing Liquid Biopsy and Hybrid PET Imaging for Prognostic Assessment in Prostate Cancer: A Focus Review.Biomolecules · 2025Review
- Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes.OncoTargets and therapy · 2025Article
- Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CT.Journal of clinical medicine · 2024Article
- Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome.European journal of nuclear medicine and molecular imaging · 2024Article
- Uncertainty quantification via localized gradients for deep learning-based medical image assessments.Physics in medicine and biology · 2024Article
- An automated methodology for whole-body, multimodality tracking of individual cancer lesions.Physics in medicine and biology · 2024Article
- Predicting Fractures Using Vertebral 18F-NaF Uptake in Prostate Cancer Patients.Journal of bone metabolism · 2023Article
- Article
- Heterogeneity of [European journal of nuclear medicine and molecular imaging · 2023Article
- UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.Molecular oncology · 2022Article
- Integrating stereotactic body radiation therapy (SBRT) and systemic treatments in oligoprogressive prostate cancer: new evidence from the literature.Clinical & experimental metastasis · 2021Article
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Tumor-Specificity Growth Factor Combined with Tumor Markers in Nuclear Medicine Imaging to Identify Prostate Cancer Osteonosus.Journal of healthcare engineering · 2021Article
- Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway.International journal of biological sciences · 2021Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntrapatient treatment response heterogeneity is under-recognized. Quantitative total bone imaging (QTBI) using PATIENTS AND
methodsMen with progressive metastatic castration-resistant prostate cancer (mCRPC) with at least two lesions on bone scintigraphy were enrolled and treated with enzalutamide 160 mg daily (ClinicalTrials.gov identifier: NCT02384382).
resultsTwenty-three men were enrolled. Duration on treatment ranged from 1.4 to 34.1 months. In general, global standardized uptake value (SUV) metrics decreased while on enzalutamide (PET2) and increased at the time of progression (PET3). The most robust predictor of PSA progression was change in SUV
conclusionWe found that the proportion of progressing lesions was low, indicating that a substantial number of lesions appear to continue to benefit from enzalutamide beyond progression. Selective targeting of nonresponding lesions may be a reasonable approach to extend benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.